
HNSCC
Thyroid Cancer
Breast Cancer
Lung Cancer
Gastric Cancer



Uliano J, et al. *ESMO Open*. 2023;8:100790.



Uliano J, et al. *ESMO Open*. 2023;8:100790.

Results From Phase 1 Study of Patritumab Deruxtecan in Combination With Osimertinib in Patients With Advanced *EGFR*-Mutated NSCLC

	Pooled RDE (5.6 mg/kg)	
	All pooled (n = 57)	Prior PBC and osimertinib (n = 44)
Confirmed ORR, % (n) [95% CI]	39 (22) [26.0-52.4]	39 (17) [24.4-54.5]
Median DOR (95% CI), mo	8.2 (4.4-8.3)	8.2 (4.0-NE)
Best overall response, n (%)		
Complete response	1 (2)	1 (2)
Partial response	21 (37)	16 (36)
Stable disease	19 (33)	13 (30)
Progressive disease	9 (16)	8 (18)
Not evaluable	7 (12)	6 (14)

Jänne PA, et al. *Cancer Discov*. 2022;12:74-89. (Published correction appears in *Cancer Discov*. 2022;12:1598.)

Results From Phase 1/2 Study of Patritumab Deruxtecan in Patients With HER3-Expressing Metastatic Breast Cancer

	HR+/HER2-, HER3 high and low All doses (n = 113)	TNBC/HER3 high All doses (n = 53)	HER2+/HER3 high All doses (n = 14)
ORR, % (95% CI)	30.1 (21.8-39.4)	22.6 (12.3-36.2)	42.9 (17.7-71.1)
Median DOR (95% CI), mo	7.2 (5.3-NR)	5.9 (3.0-8.4)	8.3 (2.8-26.4)
Best overall response, n (%)			
Complete response	0	0	0
Partial response	34 (30.1)	12 (22.6)	6 (42.9)
Stable disease	57 (50.4)	30 (56.6)	7 (50.0)
Progressive disease	13 (11.5)	9 (17.0)	1 (7.1)
Not evaluable	9 (8.0)	2 (3.8)	0

Krop IE, et al. *J Clin Oncol*. 2022;40:1002.

Efficacy of Zenocutuzumab Across Advanced NRG1 Fusion (NRG1+) Cancers

	Patients with measurable disease, inclusive of all tumor types (N = 71)	NSCLC (n = 41)	Breast cancer (n = 5)
ORR	34% (90% CI, 25-44)	35%; 14/40 pts	2/4 pts
Median DOR	9.1 mo (95% CI, 5.2-12.0)	-	-
Kaplan-Meier estimate of DOR rate at 6 mo	70%	-	-
Individual adverse events, grade ≥ 3 events	< 5%	-	-

Schram AM, et al. *Cancer Discov.* 2022;12:1233-47.

Drug Type	Name of the Compound	Mechanism of Action	Phase of Clinical Development	Sponsor
Monoclonal antibodies	Patritumab (U3-1287)	HER3-directed MoAb	Phase 3	Daiichi Sankyo Co., Ltd
	Seribantumab (MM-121)	HER3-directed MoAb	Phase 2	Elevation Oncology
	Lumretuzumab (RO5479599)	Immunoconjugate containing a glycoengineered, humanized HER3-directed MoAb; ADCC	Phase 1b/2	Hoffmann-La Roche
	GSK2849330	HER3-directed MoAb	Phase 1	GlaxoSmithKline
	CDX-3379	Human HER3-directed MoAb	Phase 2	Celldex Therapeutics
	Barecetamab (ISU104)	Fully human HER3-directed MoAb	Phase 1	ISU Abxis Co., Ltd
	AV-203	Humanized HER3-directed MoAb	Phase 1	AVEO Pharmaceuticals, Inc.
	Elgemtumab (LJM716)	HER3-directed MoAb	Phase 1/2	MorphoSys/Novartis
	HMBD-001	Anti-HER3 MoAb	Phase 1/2	Hummingbird Bioscience
	U3P1287/01 (AMG888)	Anti-HER3 MoAb	Phase 1	U3 Pharma GmbH
	SIBP-03	HER3-directed recombinant humanized MoAb	Phase 1a	Shanghai Institute of Biological Products
Bispecific antibodies	Zenocutuzumab (MCLA-128)	HER2/HER3-directed IgG bispecific antibody; ADCC	Phase 2	Merus N.V.
	Sym013	Antibody mixture composed of 6 humanized IgG1 MoAbs EGFR, HER2, and HER3 directed	Phase 1/2	Symphogen A/S
	Isitarumab (MM-141)	HER3/IGF-1R-directed bispecific antibody	Phase 2	Merrimack Pharmaceuticals
	SI-B001	EGFR/HER3-directed bispecific IgG	Phase 1	Sichuan Baili Pharmaceutical Co., Ltd
	MM-111	HER2/HER3 bispecific antibody	Phase 1	Merrimack Pharmaceuticals
	Duligotuzumab (MEHD7954A)	EGFR/HER3-directed bispecific antibody	Phase 2	Genentech/Roche
ADCs	Patritumab deruxtecan (U3 1402)	HER3-directed ADC, composed of patritumab, an HER3-directed MoAb, conjugated to the topoisomerase I inhibitor DX 8951	Phase 1/2	Daiichi Sankyo Co., Ltd

Gandullo-Sánchez L, Ocaña A, Pandiella A. HER3 in cancer: from the bench to the bedside. *J Exp Clin Cancer Res*. 2022;41(1):310.

Haikala HM, Jänne PA. Thirty years of HER3: from basic biology to therapeutic interventions. *Clin Cancer Res*. 2021;27(13):3528-3539.

Jänne PA, Baik C, Su WC, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, *EGFR*-mutated non-small cell lung cancer [published correction appears *in Cancer Discov*. 2022;12(6):1598]. *Cancer Discov*. 2022;12(1):74-89.

Krop, IE, Masuda N, Mukohara T, et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). *J Clin Oncol*. 2022;40(Suppl 16):1002.

Lyu H, Han A, Polsdofer E, Liu S, Liu B. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. *Acta Pharm Sin B*. 2018;8(4):503-510.

Nishio M, Horiike A, Murakami H, et al. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. *Lung Cancer*. 2015;88(3):275-281.

Scharpenseel H, Hanssen A, Loges S, et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. *Sci Rep*. 2019;9(1):7406.

Schneeweiss A, Park-Simon TW, Albanell J, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. *Invest New Drugs*. 2018;36(5):848-859.

Schram AM, Odintsov I, Espinosa-Cotton M, et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. *Cancer Discov*. 2022;12(5):1233-1247.

Steurer CE, Hayashi H, Su W, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without *EGFR*-activating mutations. *J Clin Oncol*. 2022;40(Suppl 16):9017.

Uliano J, Corvaja C, Curigliano G, Tarantino P. Targeting HER3 for cancer treatment: a new horizon for an old target. *ESMO Open*. 2023;8(1):100790.